Literature DB >> 1869645

Response to tumor necrosis factor in two cases of psoriasis.

P J Creaven1, H L Stoll.   

Abstract

A 70-year-old woman was treated for renal cell carcinoma with recombinant human tumor necrosis factor, 450,000 U/m2 of body surface area, daily for 5 days, once a month. She had had psoriasis for 25 years. After two courses of recombinant human tumor necrosis factor her psoriasis resolved. A 40-year-old man with severe psoriasis was subsequently treated with a total of seven complete and incomplete 5-day courses of recombinant human tumor necrosis factor at doses of 50,000 to 300,000 U/m2/day. Significant toxicity (fever, chills, hypertension, and hypotension) was encountered. Partial resolution of the lesions was seen. Tumor necrosis factor is an active agent in psoriasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1869645     DOI: 10.1016/0190-9622(91)70112-f

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

Review 1.  Immunological mechanisms involved in psoriasis.

Authors:  C E Griffiths; J J Voorhees
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor.

Authors:  M Kristensen; C Q Chu; D J Eedy; M Feldmann; F M Brennan; S M Breathnach
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

3.  The development of manifest psoriatic lesions is linked with the appearance of ICAM-1 positivity on keratinocytes.

Authors:  K Paukkonen; A Naukkarinen; M Horsmanheimo
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

4.  Association of cytokine gene polymorphisms with psoriasis in cases from the nile delta of egypt.

Authors:  Ahmad A Settin; Hanaa A Hassan; Rizk A El-Baz; Tahia A Hassan
Journal:  Indian J Dermatol       Date:  2011-05       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.